NIVOLUMAB plus IPILIMUMAB and TEMOZOLOMIDE in combination in metastatic colorectal cancer.

Primary objectives: To evaluate the efficacy, measured as 8-month PFS rate, of the combination of TMZ, NIVO and IPI in patients achieving disease control following 2-month lead-in treatment with single agent TMZ.
Primary endpoints: The primary efficacy endpoint of this study is the 8-month Progression Free Survival (PFS) rate, defined as the proportion of patients alive and progression-free.The efficacy outcome measures for this study are as follows:• Investigator-assessed PFS according to RECIST v1.1• Investigator-assessed PFS according to modified RECIST